Dr. Jade Pagkas-Bather secured her first grant from the National Institutes of Health (NIH) in June 2025, a milestone in any researcher’s career.
She planned to study basic income as a medical intervention: her randomized controlled trial would test whether monthly cash grants of $500 helped poor, HIV-positive young people in Chicago adhere to treatment. Her hypothesis was as straightforward as it was cutting.
“Maybe taking care of your HIV isn’t your priority when you’re unhoused or hungry,” Pagkas-Bather said. That summer, she had cleared peer review and was on the cusp of funding when NIH program officers began requesting changes, delivered verbally and typically via video call. “We had language stating we would include people of all gender identities. Program officers asked us to remove the term ‘gender identities.’ We had a clause noting that Black and Latinx people experience higher rates of poverty. They asked us to remove that.” There was also “concern” regarding the acronym for basic income grants (BIG).
Pagkas-Bather complied, received funding, and enrolled dozens of participants. Then, in 2026, a more fundamental demand arrived: could she remove the very concept of providing cash?
She recounted being told: “You can’t use unconditional cash transfer and you need to remove any reference to this having an impact on policy.”
Pagkas-Bather’s experience offers a window into the Trump administration’s NIH renegotiation process, an opaque and “Orwellian” political review that employs a “text analysis tool” to flag grants deemed out of “alignment” with the administration’s priorities.
The process has injected uncertainty, confusion, and distress into scientific grant-making at the NIH over the past two years. Renegotiations compel program officers—who typically take pride in shepherding critical research—to flag grants on topics the administration disfavors. Even as they do so, they must guess what the “no-no” words are: NIH Director Jay Bhattacharya has repeatedly denied the existence of a banned-word list.
“Her story is not unique,” said Shalini Agarwal, special counsel at Project Democracy, who represents Pagkas-Bather in a suit seeking class-action status and alleging the government is violating the First Amendment. “There are many other researchers in a similar situation who are being asked to subvert their own grant projects that have been peer-reviewed and approved for funding a year or more into the project.”
The total number of scientists who have undergone this process remains unknown.
Data shared exclusively with the Guardian shows renegotiations surged during the first two years of the Trump administration. In 2023, only 154 of more than 40,000 grants up for renewal changed their titles, abstracts, or public health statements—0.4% of all grants, according to an analysis by Grant Witness, an independent group that tracks canceled government grants.
Those changes increased 21-fold under the Trump administration. In 2025, 8.6% of all grants changed year-to-year, or more than 3,401 of the more than 39,000 grant continuations awarded by NIH. In 2026, 8.5% of all continuing grants changed, or 3,006 of the agency’s nearly 35,500 grants, according to Grant Witness.
In the 2027 fiscal year, which just started, 64 grants have been renewed. Three have already seen changes. In one, a study initially titled “The Black Zones,” which focused on African American neighborhoods, all mentions of “African Americans” were removed, replaced with “Black Americans.” In another, an HIV grant studying a specific viral subtype had text changed from “men and women” to “a wide range of people.”
HIV grants are almost twice as likely to have been changed, data shows, and were especially hard-hit by early cancellations. In part, many likely undertook renegotiations because the Trump administration placed severe restrictions on scientific work in South Africa. In 2025, of the 1,795 HIV-related continuing grants, 305 were changed, or 17%. In 2026, 335 of 1,609 grant continuations were changed, or 20.8%.
“The censorship that’s happening now is, I think, pretty much unprecedented,” said Jeremy Berg, a former director of the National Institute of General Medical Sciences who has closely tracked changes in NIH grant-making. “It’s very Orwellian in the sense that it’s purely double-speak,” he said. “It’s a way of exerting political control and control of the terms of the debate.”
The Guardian asked the NIH how many grants have been changed and about the “text analysis” tool employed by the agency.
The agency said “more than 5,000 new and continuation grants” have been renegotiated “to ensure the agency funds the most meritorious science, addresses urgent health needs, and sustains a robust biomedical research workforce.”
“During these grant renegotiations, grant scopes were substantively altered wherever possible to replace poorly defined, non-scientific or subjective concepts and variables with well-defined, scientific concepts that have objective and measurable variables,” an NIH spokesperson told the Guardian. “Renegotiation is a normal process that NIH has used for years on grants for various reasons. All renegotiated grants are assessed by human experts.”
The NIH’s renegotiation process was set in motion in 2025 after court battles slowed the Trump administration’s grant cancellations. As the administration sought to alter scientific studies, it developed a process of bringing grants into “alignment” with administration priorities—among them, the belief that gender is binary and that research into health equity is “unscientific.” Program officers who take pride in fostering critical research are now tasked with renegotiating grants, often intuiting what might get flagged, said National Cancer Institute branch chief Sarah Kobrin.
“They are told to contact the investigators in case the investigators want to make changes,” Kobrin said. “We are compelled. We are not calling and saying, ‘Hey, could you change these words.’”
Instead, program officers must ask: “‘Hey, you know, if you want, you could change these words and it might work out well for you.’”
“It is certainly, certainly, certainly continuing,” she said.
Now, as a historic number of Democratic doctors and scientists prepare to take office, current and former NIH leaders say Congress has years of work ahead to restore the agency.
Pagkas-Bather is one of 14 named plaintiffs in a First Amendment lawsuit arguing that such renegotiations and cancellations amount to censorship—or, in legal terms, “viewpoint-based discrimination.”
The Guardian has also covered other researchers involved in the lawsuit. In Pittsburgh, a group of researchers had funding cut for a study of Alzheimer’s disease risk in a low-income, majority-Black neighborhood. The study was cancelled by the administration, leaving hundreds of aging residents without potential dementia diagnoses.
Ultimately, Pagkas-Bather was told that if she did not remove the cash payments from her $1.3 million grant, she would need to find $1 million in funding elsewhere. Seeing no path forward, she eliminated cash grants from her study and plans to use food and transportation vouchers as her intervention. She will need to obtain consent from each participant again, since the study they enrolled in bears little resemblance to the one she is now conducting.
“Not only would [Pagkas-Bather’s study] demonstrate that money empowers people to preserve their right to exist, but also thrive,” said Leslie McGorman, senior director of policy and strategy with AIDS United. “That is so threatening to this administration.”
A federal court hearing will determine whether the lawsuit filed by Pagkas-Bather and others will receive class-action status in November.

